BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murugesan G, Correia VG, Palma AS, Chai W, Li C, Feizi T, Martin E, Laux B, Franz A, Fuchs K, Weigle B, Crocker PR. Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression. Glycobiology 2021;31:44-54. [PMID: 32501471 DOI: 10.1093/glycob/cwaa048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 van Houtum EJH, Büll C, Cornelissen LAM, Adema GJ. Siglec Signaling in the Tumor Microenvironment. Front Immunol 2021;12:790317. [PMID: 34966391 DOI: 10.3389/fimmu.2021.790317] [Reference Citation Analysis]
2 Zhao J, Yang H, Hu H, Liu C, Wei M, Zhao Y, Chen Y, Cui Y, Chen P, Xiong K, Lu Y, Yang H, Yang L. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma. Sci Rep 2022;12:10401. [PMID: 35729260 DOI: 10.1038/s41598-022-13997-2] [Reference Citation Analysis]
3 Lopes N, Correia VG, Palma AS, Brito C. Cracking the Breast Cancer Glyco-Code through Glycan-Lectin Interactions: Targeting Immunosuppressive Macrophages. Int J Mol Sci 2021;22:1972. [PMID: 33671245 DOI: 10.3390/ijms22041972] [Reference Citation Analysis]
4 Korn MA, Schmitt H, Angermüller S, Chambers D, Seeling M, Lux UT, Brey S, Royzman D, Brückner C, Popp V, Percivalle E, Bäuerle T, Zinser E, Winkler TH, Steinkasserer A, Nimmerjahn F, Nitschke L. Siglec-15 on Osteoclasts Is Crucial for Bone Erosion in Serum-Transfer Arthritis. J Immunol 2020;205:2595-605. [PMID: 33020147 DOI: 10.4049/jimmunol.2000472] [Reference Citation Analysis]
5 Jiang KY, Qi LL, Kang FB, Wang L. The intriguing roles of Siglec family members in the tumor microenvironment. Biomark Res 2022;10:22. [PMID: 35418152 DOI: 10.1186/s40364-022-00369-1] [Reference Citation Analysis]
6 Lim J, Sari-Ak D, Bagga T. Siglecs as Therapeutic Targets in Cancer. Biology (Basel) 2021;10:1178. [PMID: 34827170 DOI: 10.3390/biology10111178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Li B, Zhang B, Wang X, Zeng Z, Huang Z, Zhang L, Wei F, Ren X, Yang L. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis. Oncoimmunology 2020;9:1807291. [PMID: 32939323 DOI: 10.1080/2162402X.2020.1807291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
8 Movsisyan LD, Macauley MS. Structural advances of Siglecs: insight into synthetic glycan ligands for immunomodulation. Org Biomol Chem 2020;18:5784-97. [PMID: 32756649 DOI: 10.1039/d0ob01116a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Läubli H, Kawanishi K, George Vazhappilly C, Matar R, Merheb M, Sarwar Siddiqui S. Tools to study and target the Siglec-sialic acid axis in cancer. FEBS J 2020. [PMID: 33251699 DOI: 10.1111/febs.15647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]